Table 3. Variation of the lipidic profile

<table>
<thead>
<tr>
<th></th>
<th>Before iPCSK9 (mean)</th>
<th>After iPCSK9 (mean)</th>
<th>% of change</th>
<th>Mean of the differences</th>
<th>CI 95%</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>268±84mg/dL</td>
<td>163±75mg/dL</td>
<td>40%</td>
<td>107mg/dL</td>
<td>90-124  mg/dL</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>cLDL</td>
<td>188±79mg/dL</td>
<td>85±68mg/dL</td>
<td>55%</td>
<td>105mg/dL</td>
<td>90-121  mg/dL</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>cHDL</td>
<td>49±16mg/dL</td>
<td>52±17mg/dL</td>
<td>4%</td>
<td>-3mg/dL</td>
<td>(-6)-(-1)mg/dL</td>
<td>0.0112</td>
</tr>
<tr>
<td>TG</td>
<td>161±95mg/dL</td>
<td>149±103mg/dL</td>
<td>7%</td>
<td>19mg/dL</td>
<td>(-7)-44  mg/dL</td>
<td>0.1563</td>
</tr>
</tbody>
</table>

Table 2. Results obtained from electronic clinical history

Table 2. Variables of the study

### BACKGROUND

- Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i), Evolocumab and Alirocumab, are a new approach in order to obtain a large reduction of cLDL, which is traditionally linked to cardiovascular events.

### OBJECTIVES

- To shed light on the variation in the lipidic profile of patients treated with PCSK9i in a setting that differs from clinical trials (Real World Data).

### MATERIAL & METHODS

- Observational retrospective study, patients treated with a PCSK9i in our Hospital from Sep 2016 to Feb 2019.

#### Data from Electronic Clinical History

- demographic variables
- diagnosis
- drug and posology
- previous treatment
- prescription for primary or secondary prevention
- adverse events and discontinuation

### RESULTS

- 53 patients (33[62%] males)
- Median age: 64 years (range 35-83)

### CONCLUSION

- A high decrease of TC and cLDL is observed.
- A slight increase of cHDL levels can be assumed, though clinical trials refer a higher rise.
- No statistically significant reduction of TG was observed in this study as opposed to clinical trials.
- These findings reveal the importance of Real World Data studies, in a context where all the variables are not under control, to disclose the real efficacy of new drugs.